586 related articles for article (PubMed ID: 25225409)
1. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
2. Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E.
Siddiqui S; Schwarz F; Springer S; Khedri Z; Yu H; Deng L; Verhagen A; Naito-Matsui Y; Jiang W; Kim D; Zhou J; Ding B; Chen X; Varki N; Varki A
J Biol Chem; 2017 Jan; 292(3):1029-1037. PubMed ID: 27920204
[TBL] [Abstract][Full Text] [Related]
3. Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.
Tanida S; Akita K; Ishida A; Mori Y; Toda M; Inoue M; Ohta M; Yashiro M; Sawada T; Hirakawa K; Nakada H
J Biol Chem; 2013 Nov; 288(44):31842-52. PubMed ID: 24045940
[TBL] [Abstract][Full Text] [Related]
4. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
5. Dual actions of group B
Uchiyama S; Sun J; Fukahori K; Ando N; Wu M; Schwarz F; Siddiqui SS; Varki A; Marth JD; Nizet V
Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7465-7470. PubMed ID: 30910970
[TBL] [Abstract][Full Text] [Related]
6. Interplay Between Sialic Acids, Siglec-E, and Neu1 Regulates MyD88- and TRIF-Dependent Pathways for TLR4-Activation During
Karmakar J; Mandal C
Front Immunol; 2021; 12():626110. PubMed ID: 33763070
[TBL] [Abstract][Full Text] [Related]
7. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
8. Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties.
Yu H; Gonzalez-Gil A; Wei Y; Fernandes SM; Porell RN; Vajn K; Paulson JC; Nycholat CM; Schnaar RL
Glycobiology; 2017 Jul; 27(7):657-668. PubMed ID: 28369504
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive Siglec-E ligands on mouse aorta are up-regulated by LPS via NF-κB pathway.
Liu H; Zheng Y; Zhang Y; Li J; Fernandes SM; Zeng D; Li X; Schnaar RL; Jia Y
Biomed Pharmacother; 2020 Feb; 122():109760. PubMed ID: 31918287
[TBL] [Abstract][Full Text] [Related]
10. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
[TBL] [Abstract][Full Text] [Related]
11. Host and pathogen hyaluronan signal through human siglec-9 to suppress neutrophil activation.
Secundino I; Lizcano A; Roupé KM; Wang X; Cole JN; Olson J; Ali SR; Dahesh S; Amayreh LK; Henningham A; Varki A; Nizet V
J Mol Med (Berl); 2016 Feb; 94(2):219-33. PubMed ID: 26411873
[TBL] [Abstract][Full Text] [Related]
12. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
[TBL] [Abstract][Full Text] [Related]
14. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?
Cao H; Crocker PR
Immunology; 2011 Jan; 132(1):18-26. PubMed ID: 21070233
[TBL] [Abstract][Full Text] [Related]
15. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
16. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells.
Jia Y; Yu H; Fernandes SM; Wei Y; Gonzalez-Gil A; Motari MG; Vajn K; Stevens WW; Peters AT; Bochner BS; Kern RC; Schleimer RP; Schnaar RL
J Allergy Clin Immunol; 2015 Mar; 135(3):799-810.e7. PubMed ID: 25747723
[TBL] [Abstract][Full Text] [Related]
17. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
[TBL] [Abstract][Full Text] [Related]
18. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors.
Bochner BS
Clin Exp Allergy; 2009 Mar; 39(3):317-24. PubMed ID: 19178537
[TBL] [Abstract][Full Text] [Related]
19. Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo.
Chang YC; Olson J; Beasley FC; Tung C; Zhang J; Crocker PR; Varki A; Nizet V
PLoS Pathog; 2014 Jan; 10(1):e1003846. PubMed ID: 24391502
[TBL] [Abstract][Full Text] [Related]
20. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
